secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001367644-23-000021
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions sells travel health business to Bavarian Nordic for up to $380M
--------------------------------------------------------------------------------

- Upfront cash $270M at close; potential milestones up to $80M (CHIKV VLP development) and $30M (2026 net sales of Vaxchora/Vivotif).
- Assets sold: Vivotif, Vaxchora, CHIKV VLP, Bern manufacturing site, San Diego facilities; ~280 employees to join Bavarian Nordic.
- Transaction expected to close Q2 2023, subject to HSR, Spanish competition, and Swiss real property approvals.
- Credit agreement amended: lenders consent to sale; limited waiver of financial covenants for Q4 2022/Q1 2023 and going concern until April 17, 2023.
- Divestiture sharpens focus on medical countermeasures (ACAM2000, TEMBEXA, NARCAN) and contract manufacturing services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000021/0001367644-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000021/ebs-20230215.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer